Skip to main content

Breast Cancer

Ovarian suppression is essential in patients with moderate to high risk, hormone -receptor-positive (HR+) disease. A common treatment for these patients is ovarian suppression in combination with hormone therapy. Suppression of estrogen through sustained release of a gonadotropin-releasing hormone (GnRH) agonist, in combination with endocrine therapies, may be beneficial for premenopausal women with hormone HR+ cancer at moderate or high risk for recurrence.

Revive Research Institute is conducting a clinical research trial to assess a new therapy for ovarian suppression in the treatment of breast cancer. The purpose of our study is to assess the safety and tolerability of the investigational drug in premenopausal women with HR+, HER2- breast cancer. The investigational drug will be evaluated in patients receiving hormone therapy to induce and maintain ovarian suppression.

Participation Criteria:

  • Adults 18-55 years of age, male or female
  • Be diagnosed with Stage I, II, or III breast cancer
  • Females must be premenopausal at the time of study entry
  • Additional Criteria may apply

Our group of licensed and certified physicians will be keeping track of the patient’s progress throughout the study and will address any concerns or queries that arise regarding the research trial. The investigational treatment is free for the duration of the clinical trial and insurance is not required. All patient records and information will be kept secure and confidential. The patient will also receive compensation for their time and involvement.

Please provide YOUR contact information only.
For more info, please visit Privacy Policy.

If you require any further information, feel free to contact us at 248-564-1485.

Close Menu

Revive Research Institute, Inc.

28270 Franklin Road
Southfield, MI

T: 248-564-1485